論文

査読有り 筆頭著者 国際誌
2021年7月

Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis.

ERJ open research
  • Osamu Nishiyama
  • Kensuke Kataoka
  • Masahiko Ando
  • Shinichi Arizono
  • Akira Morino
  • Koichi Nishimura
  • Tomoya Ogawa
  • Akira Shiraki
  • Fumiko Watanabe
  • Ryo Kozu
  • Takashi Ogura
  • Yasuhiro Kondoh
  • 全て表示

7
3
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1183/23120541.00321-2021

Background: Pulmonary rehabilitation causes short-term improvement in exercise capacity, dyspnoea and health-related quality of life in idiopathic pulmonary fibrosis (IPF); however, long-term maintenance of the improvement is difficult. Nintedanib, an antifibrotic drug, has been shown to delay the worsening of pulmonary function in IPF. Therefore, the concomitant use of nintedanib with pulmonary rehabilitation is anticipated to contribute to the long-term maintenance of the pulmonary rehabilitation effects. The long-term effect of pulmonary rehabilitation under nintedanib treatment in IPF (FITNESS) study is a multicenter, randomised, prospective, parallel-group, open-label trial. Methods: The study will enrol 84 patients with IPF who have been treated with nintedanib. Patients in the pulmonary rehabilitation group will receive a programmed short-term induction pulmonary rehabilitation programme, followed by a maintenance home-based pulmonary rehabilitation programme, while patients in the control group will receive usual outpatient care. Patients in both groups will continue to receive nintedanib treatment throughout the study period. The primary end-point of the study is to compare the change in the 6-min walk distance from the baseline to 12 months between the pulmonary rehabilitation and control groups. The main secondary end-point is endurance exercise time, measured using a bicycle ergometer. Discussion: FITNESS is the first randomised controlled study to evaluate the long-term effects of pulmonary rehabilitation in IPF treated with nintedanib. This study will address the hypothesis that concomitant use of nintedanib contributes to the maintenance of long-term effects of pulmonary rehabilitation, thus leading to a comprehensive therapeutic approach of "nintedanib and pulmonary rehabilitation" in the antifibrotic era.

リンク情報
DOI
https://doi.org/10.1183/23120541.00321-2021
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34435033
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381249
ID情報
  • DOI : 10.1183/23120541.00321-2021
  • PubMed ID : 34435033
  • PubMed Central 記事ID : PMC8381249

エクスポート
BibTeX RIS